160 results about "Embolization" patented technology

Systems and methods for the intravascular treatment of clot material within a blood vessel of a human patient are disclosed herein. A method in accordance with embodiments of the present technology can include, for example, engaging an interventional device of a catheter system with clot material in a blood vessel and withdrawing the interventional device and the portion of the clot material through a guide catheter. In some embodiments, the catheter system can include an attachment / valve member coupled to a proximal portion of the guide catheter, and the method can include unsealing the attachment / valve member to facilitate withdrawing the interventional device through the attachment / valve member without significant retention of clot material within the attachment / valve member. The method can further include resealing and aspirating the guide catheter before advancing another interventional device to the clot material to again engage and remove clot material from the blood vessel.

The invention discloses a microcatheter shape determination method, a microcatheter shaping method, electronic equipment and a medium. The micro-catheter form determination method comprises the following steps: extracting a blood vessel center line of a tumor-carrying blood vessel; constructing a micro-catheter model in an initial form based on the central line of the blood vessel; calculating a directed distance field of the tumor-carrying blood vessel to obtain a boundary constraint of the micro-catheter model; and applying a load to the micro-catheter model under the boundary constraint to calculate the form of the micro-catheter. Through the scheme of the embodiment of the invention, the boundary information inside and outside the tumor-carrying blood vessel can be obtained by calculating the directed distance field of the tumor-carrying blood vessel, so that the boundary information serves as boundary constraint to be added to the calculation process of deformation of the micro-catheter model, collision detection of the micro-catheter and the tumor-carrying blood vessel is realized in the simulation process, and then a reliable micro-catheter form is formed; therefore, the shaping of the microcatheter is guided, and the smooth implementation of embolism and the surgical treatment effect are guaranteed.

Disclosed herein are clot treatment systems including integrated / systemized mechanical thrombectomy devices and clot treatment devices, and associated devices and methods. In some embodiments, a method of removing clot material from a blood vessel of patient includes inserting a catheter to proximate the clot material within the blood vessel while radially constraining a clot treatment device and an embolic protection device within the catheter. The method can further include moving the catheter proximally to deploy the clot treatment device at least partially distal to clot material within the blood vessel, and then moving the catheter further proximally to deploy the embolic protection device at least partially proximal to the clot material.

Disclosed herein are clot treatment systems including integrated / systemized mechanical thrombectomy devices and clot treatment devices, and associated devices and methods. In some embodiments, a method of removing clot material from a blood vessel of patient includes inserting a catheter to proximate the clot material within the blood vessel while radially constraining a clot treatment device and an embolic protection device within the catheter. The method can further include moving the catheter proximally to deploy the clot treatment device at least partially distal to clot material within the blood vessel, and then moving the catheter further proximally to deploy the embolic protection device at least partially proximal to the clot material.

Systems and methods can remove material of interest, including blood clots, from a body region, including but not limited to the circulatory system for the treatment of pulmonary embolism (PE), deep vein thrombosis (DVT), cerebrovascular embolism, and other vascular occlusions.

Systems and methods can remove material of interest, including blood clots, from a body region, including but not limited to the circulatory system for the treatment of pulmonary embolism, deep vein thrombosis, cerebrovascular embolism, and other vascular occlusions. The capture system can include a tubular body comprising a first end, a second end, and an axial length therebetween, the first end having an opening and a capture guide. The capture system can include one or more tensioners coupled to the capture guide. The tubular body has a first configuration in which the first end and the capture guide are expanded while the second end and a majority of the tubular body remains compressed. The tubular body is transformable to a second configuration by application of tension by the tensioners. The catheter can remove a large volume of clot.

Systems and methods for the intravascular treatment of clot material within a blood vessel of a human patient are disclosed herein. A method in accordance with embodiments of the present technology can include, for example, engaging an interventional device of a catheter system with clot material in a blood vessel and withdrawing the interventional device and the portion of the clot material through a guide catheter. In some embodiments, the catheter system can include an attachment / valve member coupled to a proximal portion of the guide catheter, and the method can include unsealing the attachment / valve member to facilitate withdrawing the interventional device through the attachment / valve member without significant retention of clot material within the attachment / valve member. The method can further include resealing and aspirating the guide catheter before advancing another interventional device to the clot material to again engage and remove clot material from the blood vessel.

Systems and methods can remove material of interest, including blood clots, from a body region, including but not limited to the circulatory system for the treatment of pulmonary embolism (PE), deep vein thrombosis (DVT), cerebrovascular embolism, and other vascular occlusions.

A device and method for intravascular treatment of an embolism, and particularly a pulmonary embolism, is disclosed herein. One aspect of the present technology, for example, is directed toward a clot treatment device that includes a support member having a plurality of first clot engagement members and second clot engagement members positioned about the circumference of a distal portion of the support member. In an undeployed state, individual first clot engagement members can be linear and have a first length, and individual second clot engagement members can be linear and have a second length that is less than the first length. The clot engagement members can be configured to penetrate clot material along an arcuate path and hold clot material to the clot treatment device.

The invention relates to the technical field of image processing, and discloses a pulmonary embolism focus segmentation method and system based on image recognition, and a storage medium. The method comprises the following steps: extracting a multi-level blood vessel topological structure of a CTPA image through blood vessel diameter gradient analysis; modeling blood vessel density distribution by using a Weibull mixed model to obtain embolism characteristic parameters; the pixel embolism probability is estimated through variational Bayesian reasoning, and a focus distribution diagram is generated; performing multi-scale feature fusion on the lesion probability graph to obtain a segmentation boundary; and obtaining a final embolism focus segmentation result based on the vascular connectivity constraint optimization boundary. The problems that blood vessel level differentiation processing cannot be achieved, and accurate probability modeling and anatomical constraint verification are lacked are solved. The accuracy of pulmonary embolism focus segmentation is improved.

Disclosed herein are clot treatment systems including mechanical thrombectomy devices and clot treatment devices, and associated devices and methods. In some embodiments, a method of removing clot material from a blood vessel of patient includes inserting a catheter to proximate the clot material within the blood vessel while radially constraining a clot treatment device and an embolic protection device within the catheter. The method can further include moving the catheter proximally to deploy the clot treatment device at least partially distal to clot material within the blood vessel, and then moving the catheter further proximally to deploy the embolic protection device at least partially proximal to the clot material. The clot treatment device can include one or more relief features configured to release captured clot material if the force on the clot treatment device exceeds a threshold.

The invention relates to the technical field of composite material preparation, in particular to high-mechanical-property granular hydrogel and a preparation method and application thereof.The high-mechanical-property granular hydrogel is prepared by mixing gelatin nano-particles, calcium carbonate nano-particles, ferric oxide nano-particles and a sodium alginate solution under the alkaline condition, then adding gluconic acid-delta-lactone, and conducting stirring, standing and drying to obtain the high-mechanical-property granular hydrogel. Particle hydrogel with high mechanical property is prepared and is simply recorded as Ca-Alg / MCG, and the gel system is endowed with the catheter injectable property, the blood vessel deliverable property and the intravascular hardenability property. The hydrogel can be delivered to small blood vessels of tumors, the mechanical property can be gradually enhanced along with the change of time, and the embolism effect of the granular hydrogel in the blood vessels is further improved. Meanwhile, the magnetic nanoparticles endow the hydrogel with the magnetic-thermal response capability, the temperature can be rapidly increased under an alternating magnetic field, tumor cells are further killed, and the hydrogel shows an excellent embolism effect in a rabbit kidney embolism model and a liver cancer rabbit embolism model.

Disclosed herein are clot treatment systems including mechanical thrombectomy devices and clot treatment devices, and associated devices and methods. In some embodiments, a method of removing clot material from a blood vessel of patient includes inserting a catheter to proximate the clot material within the blood vessel while radially constraining a clot treatment device and an embolic protection device within the catheter. The method can further include moving the catheter proximally to deploy the clot treatment device at least partially distal to clot material within the blood vessel, and then moving the catheter further proximally to deploy the embolic protection device at least partially proximal to the clot material. The clot treatment device can include one or more relief features configured to release captured clot material if the force on the clot treatment device exceeds a threshold.

Systems and methods for the intravascular treatment of clot material within a blood vessel of a human patient are disclosed herein. A method in accordance with embodiments of the present technology can include, for example, engaging an interventional device of a catheter system with clot material in a blood vessel and withdrawing the interventional device and the portion of the clot material through a guide catheter. In some embodiments, the catheter system can include an attachment / valve member coupled to a proximal portion of the guide catheter, and the method can include unsealing the attachment / valve member to facilitate withdrawing the interventional device through the attachment / valve member without significant retention of clot material within the attachment / valve member. The method can further include resealing and aspirating the guide catheter before advancing another interventional device to the clot material to again engage and remove clot material from the blood vessel.

Disclosed herein are clot treatment systems including mechanical thrombectomy devices and clot treatment devices, and associated devices and methods. In some embodiments, a method of removing clot material from a blood vessel of patient includes inserting a catheter to proximate the clot material within the blood vessel while radially constraining a clot treatment device and an embolic protection device within the catheter. The method can further include moving the catheter proximally to deploy the clot treatment device at least partially distal to clot material within the blood vessel, and then moving the catheter further proximally to deploy the embolic protection device at least partially proximal to the clot material. The clot treatment device can include one or more relief features configured to release captured clot material if the force on the clot treatment device exceeds a threshold.

The invention provides a thrombus removal catheter for intracavity treatment, and belongs to the technical field of medical instruments. Comprising a first guide rod and a cutter body, a guide wire is inserted into the first guide rod, the outer wall of the first guide rod is slidably sleeved with a first isolation sleeve, the outer wall of the first isolation sleeve is slidably sleeved with a second guide rod, and the supporting assembly is used for supporting blood vessels of a patient. By arranging the supporting assembly, thrombus which is separated or falls off from the inner wall of a blood vessel can be blocked and protected, the thrombus is prevented from flowing to the far-end blood vessel along with blood, and the phenomenon of far-end embolism is avoided; the supporting assembly can collect thrombus separated in the cutting process or falling off from the inner wall of a blood vessel in a unified mode, the collected thrombus is discharged out of the body of a patient, the phenomenon of far-end embolism is avoided, and it is guaranteed that the thrombus is not left in the whole thrombus removing process.

The invention provides a pulmonary artery embolism imaging method, and relates to the field of magnetic resonance imaging. According to the specific implementation scheme, an acquisition window is determined according to electrocardio data and diaphragm navigation data of an adaptive patient; according to the collection window, original frequency domain data are collected in a Cartesian filling mode; performing phase compensation on the original frequency domain data by utilizing pulmonary artery pulse vector field modeling and a dynamic compensation algorithm to obtain proportionality coefficient spatial data; and performing compressed sensing reconstruction on the proportionality coefficient spatial data to generate a three-dimensional pulmonary artery image. The scheme is used for detecting pulmonary artery embolism in the free breathing state, no contrast agent is needed, radiation is avoided, and the universality of applicable people and the inspection safety are improved. According to the technology, by reducing artifact interference and optimizing image quality and scanning efficiency, rapid and accurate diagnosis is achieved, the comfort level of a patient and clinical diagnosis efficiency are remarkably improved, and the technology has important application value and social benefits.

The invention provides an angiography CT (Computed Tomography) image-based early-stage pulmonary artery micro embolism detection method, which comprises the following steps of: extracting pulmonary parenchyma, and segmenting a small pulmonary blood vessel to obtain a pulmonary blood vessel tree; network weight is updated based on a neural evolution calculation method, and lung arteries and veins are separated; and obtaining a complete pulmonary artery tissue from a pulmonary artery and vein separation result, establishing a level set evolution model to enable the curve to be accurately evolved to the edge of a normal pulmonary artery tissue, and removing the normal pulmonary artery tissue to obtain a pulmonary embolism focus tissue so as to obtain a pulmonary embolism detection result. The method provided by the invention can accurately detect the micro embolism part at the early stage of pulmonary embolism, and has important clinical application value.

The invention relates to a liquid embolism agent as well as a preparation method and an application method thereof, and belongs to the technical field of medical instruments. The invention discloses a liquid embolism agent which has a developing function and a magnetic hyperthermia function. The liquid embolism agent comprises a polymer, a solvent and carbonyl iron powder, wherein the carbonyl iron powder has a developing function and a magnetic hyperthermia function. The liquid embolism agent is prepared by using the compound carbonyl iron powder which has developing and magnetic hyperthermia effects at the same time, so that when the liquid embolism agent is implanted into a tumor focus area through a microcatheter to embolize tumor blood vessels, the embolism process can be monitored through developing and positioning of the carbonyl iron powder, and meanwhile, under an external alternating magnetic field, the embolism effect can be effectively improved. The carbonyl iron powder generates a magnetocaloric effect under the action of an external magnetic field, so that a focus part is locally heated, and tumor cell regeneration is thoroughly eliminated and eradicated.

The invention belongs to the technical field of biological detection, and particularly discloses a cardiovascular marker substance control product and a preparation method thereof, the cardiovascular marker substance control product comprises a serum matrix, an antigen, a preservative and a stabilizer; the antigens comprise a cardiac troponin I antigen, a creatine kinase isoenzyme antigen, a myoglobin antigen, an amino-terminal brain natriuretic peptide precursor antigen, a brain natriuretic peptide antigen, a D-dimer antigen, a heart-type fatty acid binding protein antigen, a myeloperoxidase antigen and a lipoprotein phospholipase A2 antigen; the stabilizer comprises at least one of D-trehalose, cane sugar, glycine, inositol and polyethylene glycol. The cardiovascular marker substance control substance disclosed by the invention can cover various cardiovascular disease markers including heart failure, pulmonary artery embolism, vasculitis, atherosclerosis, myocardial injury, myocardial infarction and the like. The quality control product disclosed by the invention can be used as a third-party quality control product for screening cardiovascular diseases and performing indoor and interventricular quality control on an auxiliary diagnosis and measurement system.

The present invention relates to (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4'-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of formula (I), preferably in the form of one of its salts or solvates or hydrates, preferably (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4'-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid monohydrate (I) of formula (IMI) or (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2- The present invention relates to a pharmaceutical dry powder formulation comprising {[3-chloro-4'-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid monohydrate (II) in combination with a lactose carrier comprising lactose monohydrate as a mixture of coarse and fine lactose, a process for producing such a pharmaceutical dry powder formulation, and its application for use in the treatment of cardiopulmonary disorders such as pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH), and pulmonary hypertension (PH) associated with chronic lung diseases (group 3 PH), such as pulmonary hypertension in chronic obstructive pulmonary disease (PH-COPD) and pulmonary hypertension associated with idiopathic interstitial pneumonia (PH-IIP).

The invention provides a radial artery radiography cannula, and relates to the technical field of medical instruments, the radial artery radiography cannula comprises an inner tube and an outer cannula, the inner tube comprises an inner tube catheter seat and an inner tube body, the outer cannula comprises an outer cannula catheter seat and an outer cannula body, the inner tube catheter seat is provided with a connector part, and the connector part can be connected with the outer cannula catheter seat in a matched mode. The inner tube body penetrates into the outer tube body, the outer tube and the inner tube can be locked and matched through the connector part and the outer tube catheter base, the adaptability is good, gas embolism or thrombus is not prone to being caused, the end of the middle cavity is sealed through the locking position, blood cannot overflow, and the influence on surgical operation is avoided; the inner tube and the outer tube are synchronous when a large blood vessel on an arch is subjected to super-selection, the outer tube and the inner tube are separated after the outer tube points to a target blood vessel, super-selection is conducted towards the far end to the target blood vessel under the support of the guide wire and the inner tube, the controllability of the catheter is improved, and the super-selection difficulty is reduced.

The invention discloses a modified polypeptide as well as a preparation method and application thereof, the preparation method comprises the following steps: on the basis of solid-phase synthesis of RADA16, 1-hydroxybenzotriazole and benzotriazole-N, N, N ', N'-tetramethylurea hexafluorophosphate are adopted as condensing agents, N, N-diisopropylethylamine-containing N, N-diisopropylethylamine is added into the condensing agents, and a reaction is carried out for 2-4 hours to obtain the modified polypeptide. And adding amino-terminated or carboxyl-terminated polyethylene glycol or amino-containing chitosan oligosaccharide into N, N-dimethylformamide for condensation, cutting polypeptide from the resin after the reaction is completed, precipitating, washing, re-dissolving and freeze-drying to obtain the polypeptide. The polypeptide provided by the invention has the characteristic of forming hydrogel through self-assembly in a specific medium, and the gel forming time of the polypeptide is within 21-60 seconds and is obviously faster than that of RADA peptide (gel forming in 150 seconds) under the same condition; the polypeptide modified by the polyethylene glycol or the chitosan oligosaccharide can spontaneously form gel after being injected into the blood vessel so as to embolize the blood vessel, and the embolism is long in stabilization time and stable, and meets the actual clinical requirements.

The invention discloses a prediction model for predicting a liver cancer combined treatment effect based on multi-mode MRI radiomics characteristics and a construction method and application thereof, and belongs to the technical field of liver cancer treatment effect prediction. In order to solve the problem that only part of liver cancer patients can benefit from an arterial chemoembolization combined targeted immunotherapy scheme at present, the invention proposes that before combined therapy, MRI radiomics characteristics and clinical factors are enhanced through noninvasive multi-modal comparison, multiple machine learning models are established, and the model learning model is used for learning the liver cancer patients. The tumor treatment response of arterial chemoembolism combined with molecular targeting and immunotherapy is predicted, and the applicability of the radiomics model is verified by using an external data set; besides, the radiomics model is combined with a clinical model, so that the method has more excellent prediction efficiency, and the radiomics features provide incremental prediction value for clinical factors. The prediction model can predict the combined treatment effect of the liver cancer patients, so that corresponding more effective and reasonable treatment schemes are selected for different patients before treatment.

The invention discloses a pulmonary arterial hypertension risk prediction model based on night hypoxia and cardiac ultrasound indexes and a construction method thereof, and the method comprises the steps: collecting cardiac ultrasound examination indexes, right cardiac catheter examination data and night sleep respiration monitoring data of a patient with chronic thromboembolic pulmonary diseases; the method comprises the following steps: according to hemodynamic data measured by right heart catheter examination, grouping into a CTEPD accompanied PH (hereinafter referred to as CTEPH) group and a CTEPD non-accompanied PH group, and carrying out statistical analysis on all collected data; risk factors related to the CTEPH are screened out; and screening CTEPH prediction model variables and constructing a pulmonary arterial hypertension risk prediction model. According to the method, the pulmonary arterial hypertension risk prediction model based on the night hypoxia and cardiac ultrasound indexes is constructed, the CTEPH risk is diagnosed only by combining the hypoxia indexes with the cardiac ultrasound indexes, non-invasive risk assessment is achieved, no harm is caused to patients, operation is easy and convenient, the model performance is good, and the method can be popularized and popularized in hospitals at all levels in China and is wide in applicability.

The invention belongs to the field of biomedical materials, and particularly relates to a coagulation-promoting embolism microsphere and a preparation method thereof. The sericin-based embolism microspheres are creatively prepared, and the sericin membrane layer on the surface of the microspheres can prevent the risk that a catheter is solidified during an operation due to thrombin burst release during the operation. On the other hand, sericin in the microspheres has excellent water absorption swelling property and lubricity, and is beneficial to embolism and prevention of reflux; moreover, sericin molecules contain a large amount of hydroxyl and carboxyl, so that the chelation of blood coagulation factor calcium ions is greatly improved. In addition, thrombin factors are loaded into the microspheres, calcium ions are chelated on the surfaces of the microspheres, the microspheres are endowed with rapid embolism capacity through the superimposed effect, blood flow blocking of target blood vessels can be effectively accelerated, and reflux is prevented. The prepared procoagulant embolism microspheres are suitable for being applied to treatment of vascular-rich tumors of the brain and can effectively prevent mistaken closure of many complex functional blood vessels of the brain due to reflux.

A multifunctional auxiliary device for in-situ dialysis catheter replacement. A guide wire sequentially passes through a puncture tube. As the sharp end of the puncture tube pierces through a blocking membrane, it passes through a guiding catheter, passes through a dialysis catheter connected to a connecting tube along the guiding catheter, and penetrates into the human body along the dialysis catheter. Compared with the prior art, the present invention has the following advantages: during the replacement of a hemodialysis catheter, when the guide wire enters the blood vessel, the blood leakage along the gaps between the guide wire and the catheter lumen in the catheter is significantly reduced; it avoids serious complications such as air embolism caused by air entering the body along the guide wire; it reduces the contact with the original catheter during the operation, making the sterile area in the operation process cleaner and reducing the infection incidence rate. The operator can also complete the operation calmly, relatively improving the safety of the newly placed catheter and the effect of the new catheter. In addition, the injection connecting tube connected to a syringe can be used for angiography through a side hole to distinguish the reasons for the poor function of the original catheter, evaluate the local vascular conditions, and help to propose a better catheter treatment plan.

The invention discloses a cryoablation catheter system for pulmonary artery stent internal restenosis, and belongs to the field of medical instruments, the cryoablation catheter system comprises a catheter main body arranged on a guide wire, the catheter main body is provided with a treatment assembly, the treatment assembly is located at the far end of the catheter main body, the catheter main body is provided with a control handle, and the control handle is located at the far end of the catheter main body. The control handle is located at the near end of the catheter body, and the treatment assembly comprises a near-end balloon, a far-end balloon and a freezing balloon. When the near-end balloon and the far-end balloon are simultaneously full, a closed treatment cabin isolated from near-end blood flow and far-end blood flow can be formed in a blood vessel of a target treatment section, the freezing balloon is located in the treatment cabin, the closed treatment cabin thoroughly eliminates the blood flow hot pool effect, cold is prevented from being taken away by the blood flow, and the treatment effect is improved. Freezing energy is intensively acted on a diseased region, so that the ablation efficiency and accuracy are improved; meanwhile, thrombus, tissue debris and whole body blood flow which fall off in the treatment process are isolated, the risk of far-end embolism is reduced from the source, and damage to the blood vessel wall is avoided.

The invention discloses a coated yttria-90 loaded radioactive microsphere and a preparation method and application thereof, and relates to the technical field of radioactive microsphere preparation, and the preparation method comprises the following steps: preparing a polyvinyl alcohol microsphere by using a microfluidic technology; the preparation method comprises the following steps: labeling polyvinyl alcohol microspheres with yttrium-90 radionuclide to obtain yttrium-90 loaded radiation microspheres; and coating the polylactic acid-glycolic acid copolymer on the surface of the yttria-90 loaded radioactive microsphere to obtain the coated yttria-90 loaded radioactive microsphere. The composite radioactive microspheres with uniform particle size, stable radioactivity and controllable characteristics can be obtained, and the composite radioactive microspheres are expected to be applied to transcatheter arterial radioembolism (TARE) treatment of liver cancer.

The systems and methods of the present invention can remove target material (including blood clots) from body parts (including but not limited to the circulatory system) for the treatment of pulmonary embolism (PE), deep vein thrombosis (DVT), cerebral vascular embolism, and other vascular obstructions. The capture system may include a tubular body and an end having an opening and a capture guide. In some embodiments, the body or funnel tip of the catheter is expandable.